Sector Investors News and Insights

HUTCHMED has announced the publication of Phase III ESLIM-01 results in The Lancet Haematology.

Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior…

Read More: https://www.globenewswire.com/news-release/2024/06/17/2899307/0/en/HUTCHMED-Highlights-Publication-of-Phase-III-ESLIM-01-Results-in-The-Lancet-Haematology.html

Scroll to Top

Subscribe to our Newsletter

Stay updated with the latests analysis and insights fromm etfsector.com